NO981282L - Calcitriolderivater og deres anvendelser - Google Patents

Calcitriolderivater og deres anvendelser

Info

Publication number
NO981282L
NO981282L NO981282A NO981282A NO981282L NO 981282 L NO981282 L NO 981282L NO 981282 A NO981282 A NO 981282A NO 981282 A NO981282 A NO 981282A NO 981282 L NO981282 L NO 981282L
Authority
NO
Norway
Prior art keywords
compounds
vitamin
modified
calcitriol
modified compound
Prior art date
Application number
NO981282A
Other languages
English (en)
Other versions
NO981282D0 (no
Inventor
Hector F Deluca
Heinrich K Schnoes
Zu Yun Cai
Mary E Phelps
Connie M Smith
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/531,403 external-priority patent/US5952317A/en
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of NO981282D0 publication Critical patent/NO981282D0/no
Publication of NO981282L publication Critical patent/NO981282L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En fremgangsmåte for å behandle metaboliske sykdommer slik som osteoporose, samt andre sykdomstilstander som kan behandles med vitamin D- forbindelser, omfatter å administrere en effektiv mengde av en eller flere modifiserte vitamin D- forbindelser. Den modifiserte forbindelsen inneholder en typisk vitamin D-kjerne, men med in vivo hydrolyserbare grupper på en eller flere posisjoner l, 3 og 25 karbonene. Tiden for kon- versjon av den modifiserte forbindelsen til sin aktive form, slik som calcitriol, kan bli regulert for dermed å fremskaffe kontollert frigivelse av forbindelser in vivo over tid, ved å endre eller modifisere de hydrolyserbare gruppene.
NO981282A 1995-09-21 1998-03-20 Calcitriolderivater og deres anvendelser NO981282L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53186795A 1995-09-21 1995-09-21
US08/531,403 US5952317A (en) 1995-09-21 1995-09-21 Calcitriol derivatives and their uses
PCT/US1996/015184 WO1997011053A1 (en) 1995-09-21 1996-09-20 Calcitriol derivatives and their uses

Publications (2)

Publication Number Publication Date
NO981282D0 NO981282D0 (no) 1998-03-20
NO981282L true NO981282L (no) 1998-05-22

Family

ID=27063537

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981282A NO981282L (no) 1995-09-21 1998-03-20 Calcitriolderivater og deres anvendelser

Country Status (9)

Country Link
EP (1) EP1021401A1 (no)
JP (1) JP3372259B2 (no)
KR (1) KR100327922B1 (no)
AU (1) AU717238B2 (no)
CA (1) CA2229316C (no)
HU (1) HUP9802303A3 (no)
NO (1) NO981282L (no)
NZ (2) NZ319819A (no)
WO (1) WO1997011053A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
WO2001011986A1 (en) * 1999-08-17 2001-02-22 Wisconsin Alumni Research Foundation Animal feed containing hydrolyzable calcitriol derivatives
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
WO2001040177A2 (en) 1999-12-02 2001-06-07 Women And Infants Hospital Esters of vitamin d3 and uses thereof
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
AU2005216651A1 (en) 2004-03-01 2005-09-09 Bioxell Spa Treatment of interstitial cystitis with vitamin D compounds
CA2586679A1 (en) 2004-11-12 2006-05-18 Bioxell Spa Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US8592401B2 (en) 2007-04-25 2013-11-26 Proventiv Therapeutics, Llc Methods and compounds for vitamin D therapy
HUE073014T2 (hu) 2007-04-25 2025-12-28 Opko Renal Llc Eljárás a másodlagos hyperparathyreoidismus biztonságos és hatékony kezelésére és megelõzésére krónikus vesebetegség esetén
EP2281058B1 (en) 2008-04-02 2016-06-29 Opko Ireland Global Holdings, Ltd. Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
KR101983654B1 (ko) * 2018-07-24 2019-05-29 한국과학기술원 Cfc 증후군 환자의 발달 저해를 완화할 수 있는 치료용 조성물
CN114681467B (zh) * 2022-03-30 2024-03-12 南通华山药业有限公司 一种阿法骨化醇杂环酯类衍生物在制备抗肿瘤药物中的应用
CN114656413B (zh) * 2022-03-30 2024-04-09 南通华山药业有限公司 一种阿法骨化醇杂环酯类衍生物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4195027A (en) * 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4206131A (en) * 1978-06-19 1980-06-03 The Upjohn Company Compounds and process
US4188345A (en) * 1978-07-26 1980-02-12 Wisconsin Alumni Research Foundation Fluorovitamin D compounds and processes for their preparation
JPS5846508A (ja) * 1981-09-14 1983-03-18 日本石油化学株式会社 導電性材料の製法
GB2126234B (en) * 1982-07-26 1986-05-21 Wisconsin Alumni Res Found Novel vitamin d analogs
JPH0825993B2 (ja) * 1990-08-20 1996-03-13 大同ほくさん株式会社 ビタミンｄ２およびｄ３又は活性型ビタミンｄ２およびｄ３の製造方法，並びにその中間体
JPH05339230A (ja) * 1992-03-12 1993-12-21 Nisshin Flour Milling Co Ltd 活性型ビタミンｄ２及びその誘導体の製造法
JP3182215B2 (ja) * 1992-06-26 2001-07-03 日清製粉株式会社 １−アシルオキシビタミンｄ誘導体

Also Published As

Publication number Publication date
AU7242696A (en) 1997-04-09
CA2229316A1 (en) 1997-03-27
JPH11511475A (ja) 1999-10-05
NZ319819A (en) 2000-02-28
KR100327922B1 (ko) 2002-05-09
CA2229316C (en) 2005-04-12
JP3372259B2 (ja) 2003-01-27
EP1021401A1 (en) 2000-07-26
NZ501318A (en) 2001-07-27
NO981282D0 (no) 1998-03-20
MX9801943A (es) 1998-08-30
HUP9802303A3 (en) 1999-05-28
HUP9802303A2 (hu) 1999-02-01
AU717238B2 (en) 2000-03-23
KR19990063628A (ko) 1999-07-26
WO1997011053A1 (en) 1997-03-27

Similar Documents

Publication Publication Date Title
NO981282L (no) Calcitriolderivater og deres anvendelser
CO5160365A1 (es) Celulosa microfibrilar estabilizada
BR9808953A (pt) Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica
BR9608547A (pt) Método para melhorar a sa·de animal
NO20010466L (no) Synergistiske og residuelle pesticide preparater inneholdende eteriske planteoljer
AU2118488A (en) Improvements in or relating to methods of treating damaged skin
NO971051L (no) Middel for å öke produksjonen av oppdretts- og produksjonsdyr i fjærfeindustrien
PT1100516E (pt) Extratos de matricaria (tanacetum parthenium) contra doencas inflamatorias
MX9304435A (es) Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.
NO174764C (no) Fremgangsmåte for fremstilling av et preparat som er virksomt ved behandling av hyperkeratotiske og andre hudsykdommer
ATE229809T1 (de) Verwendung von magnesium enthaltenden verbindungen zur behandlung oder prophylaxe von krebs- und autoimmunkrankheiten
ES2017808A6 (es) Un metodo para prepara una composicion para inhibir el crecimiento indeseado o patologico de celulas o tejidos.
ATE448788T1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
EP0780129A3 (en) Adrenal cortical steroid containing external therapeutic composition for dermatitis
NO20001758L (no) FremgangsmÕter og blandinger for behandling av leddgikt
SE8107468L (sv) Komposition for behandling av psoriasis pa basis av en 1,8-dihydroxi-9-antron substituerad i 10-stellningen
ES2093226T3 (es) Retinoides sustituidos con un ciclo ditiano y su empleo, procedimiento de preparacion de dichos compuestos, composiciones cosmetica y farmaceutica que los contienen y empleo terapeutico de esta ultima.
AP9801416A0 (en) Method Of treating a plant disease.
NO981594L (no) Behandling av infeksjoner forÕrsaket av Helicobacter pylori
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
JPS51148971A (en) Surfactant containing waste water treatment
JPS5435218A (en) Reduction of phytotoxicity of paddy-rice plant
JPS52109759A (en) Purification method of waste treating solutions of photography using b acteria
JPS5233353A (en) Starch containing waste solution treatment method
JPS53145568A (en) Surface treating method

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application